Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO1998052572) USE OF TAUROLIDINE FOR TREATMENT OF LEUKEMIAS
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1998/052572 International Application No.: PCT/US1998/010494
Publication Date: 26.11.1998 International Filing Date: 22.05.1998
Chapter 2 Demand Filed: 15.12.1998
IPC:
A61K 31/549 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
54
having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame
549
having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
Applicants:
OKLAHOMA MEDICAL RESEARCH FOUNDATION [US/US]; 825 N.E. 13th Street Oklahoma City, OK 73104, US (AllExceptUS)
MORRISSEY, James, H. [US/US]; US (UsOnly)
HAMIK, Anne [US/US]; US (UsOnly)
Inventors:
MORRISSEY, James, H.; US
HAMIK, Anne; US
Agent:
HANSEN, Eugenia, S. ; Sidley & Austin Suite 3400 717 N. Harwood Dallas, TX 75201-6507, US
Priority Data:
60/047,64222.05.1997US
Title (EN) USE OF TAUROLIDINE FOR TREATMENT OF LEUKEMIAS
(FR) UTILISATION DE TAUROLIDINE POUR LE TRAITEMENT DE LEUCEMIES
Abstract:
(EN) Taurolidine (taurolin; tauroline; 4,4'-methylenebis(perhydro-1,2,4-thiadiazin 1,1-dioxide) has been found to be an effective agent for treating patients inflicted with monocytic and/or myeloid leukemias through the induction of apoptosis in leukemia cells. Concentrations of taurolidine in the range of 50 to 100 $g(m)g/ml induced apoptosis in 75 % of peripheral blood monocytes incubated in culture medium within six hours. Further, 100 $g(m)g/ml taurolidine induced apoptosis in 92 % of granulocytes incubated in culture medium within six hours. Taurolidine was also effective in reducing the hypercoagulable state associated with tissue factor expression on leukemia cells, providing a means by which the incidence and degree of severity of coagulopathies associated with tissue factor expression can be reduced in leukemia patients. Preferred therapeutic dosages for treatment of leukemias are from about 10 to about 500 mg/kg body weight. Most preferred is a dose that results in a 200 $g(m)g/ml concentration in the plasma, which is typically about 150 mg/kg body weight.
(FR) L'invention concerne la découverte selon laquelle la taurolidine (taurolin; tauroline; 4,4'-méthylènebis(perhydro-1,2,4-thiadiazine 1,1 dioxide) constitue un agent efficace pour traiter des patients souffrant de leucémie monocytaire et/ou myéloïde, par provocation de l'apoptose des cellules leucémiques. Des concentrations de taurolidine de l'ordre de 50 à 100 $g(m)g/ml ont provoqué en moins de six heures l'apoptose de 75 % de monocytes sanguins périphériques incubés dans un milieu de culture. De plus, 100 $g(m)g/ml de taurolidine ont provoqué en moins de six heures l'apoptose de 92 % de granulocytes incubés dans un milieu de culture. La taurolidine a également été efficace pour réduire l'état d'hypercoagulation associé à l'expression du facteur de tissu sur des cellules leucémiques, ce qui fait d'elle un moyen permettant de réduire la fréquence et le degré de gravité des coagulopathies associées à l'expression du facteur de tissu chez des sujets leucémiques. Des doses thérapeutiques préférées pour le traitement de leucémies se situent entre environ 10 à environ 500 mg/kg de poids corporel. La dose idéale est une dose permettant d'obtenir une concentration de 200 $g(m)g/ml dans le plasma, ce qui revient généralement à une dose d'environ 150 mg/kg de poids corporel.
Designated States: AU, CA, JP, US
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
EP0983069US6303596CA2290537AU1998075906AU2001065619